J&J's anti-tax maneuvering revives repatriation debate; Novartis releases Galvus data;

@FiercePharma: Big Pharma's Japanese sales gain as U.S., Europe lag. News | Follow @FiercePharma

> Johnson & Johnson's ($JNJ) Synthes deal--and the financing plan that helped it minimize U.S. taxes--is reviving a debate over repatriation taxes. Report

> Novartis ($NVS) said its diabetes drug Galvus delivered better blood sugar reductions in combination with insulin or insulin plus metformin compared with placebo and launched a long-term study of the drug in recently diagnosed patients. Release

> PDL BioPharma said it expects about $125 million in royalty revenue based on growing sales of Genentech's Herceptin and Lucentis, and Biogen Idec's ($BIIB) Tysabri. News

> Germany's Medigene and Denmark's Azanta have teamed up on marketing the genital warts treatment Veregen in the Nordic countries. Item

> A federal judge gave final approval to Novartis' previously agreed $99 million settlement with more than 7,000 sales reps claiming unpaid overtime. Story

> The U.K.'s cost-effectiveness watchdog has unveiled a new smartphone app giving doctors access to the British Naitonal Formulary of prescription drugs. Article

Biotech News

@FierceBiotech: Devicemakers should rely more upon outsourcing and CROs, study says. Report | Follow @FierceBiotech

@JohnCFierce: Just heard we sold out on the 330-seat venue for our R&D breakfast in Boston Tuesday. Which is pretty cool. Hope to see you there. | Follow @JohnCFierce

@RyanMFierce: Some lab and IT workers targeted in 400 layoffs at AstraZeneca in Sweden. Item | Follow @RyanMFierce

> Third Rock funds $40M launch of San Francisco blood disease biotech. News

> Novo Nordisk centers juvenile diabetes work at new R&D hub. Story

> Economy blamed for jobs shortfall in Bay State's $1B biotech plan. More

> Bugs living in humans breed biotech startups. Article

Medical Devices News

@FierceMedDev: Invuity says its $25M series D round comes even as surgical tools aren't otherwise drawing much investor interest. Item | Follow @FierceMedDev

@MarkHFierce:  We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey| Follow @MarkHFierce

> Armed with CE mark, Dexcom rolls out next-gen glucose monitor. Article

> Edwards' stock soars after FDA panel nod on expanded Sapien valve use. Story

> MIT's fuel cell uses glucose to power brain implants. News

> JustRight, maker of a tissue-sealing device, grabs $6.5M. Item

CRO News

@NesaNFierce: FierceCRO just posted its Top 5 Strategic CRO/Pharma Partnerships list! Check it out and let me know what you think! Special Report | Follow @NesaNFierce

> Eli Lilly bets on insulin research and generics manufacturing in China. Article

> Former Sandia employee faces embezzlement charges after stealing nanotech info. Story

> Devicemakers should rely more upon outsourcing and CROs, study says. More

> Zeincro Group and Trial Masters merge to expand Eastern European reach. Report

Pharma Manufacturing News

@EricPFierce: Filtrona completes its acquisition of Lymtech Scientific. News | Follow @EricPFierce

> Smaller Indian drugmakers need support to improve GMPs. Item

> Cuts in drug manufacturing felt in U.K. industrial output. Article

> Loss for CMO Patheon smaller than expected. Story

> Pakistan's ex-health director has heart attack under questioning. Report

Vaccines News

> GeoVax: Meeting the HIV vaccine challenge. Column

> VaxInnate bird flu shot flies into Phase I. More

> Novartis, Cytos Alzheimer's vax shows immune response. Item

> New HPV vax could treat cancer rather than prevent it. News

And Finally... In a medical school commencement address, FDA Commissioner Margaret Hamburg urged young doctors to listen to their hearts and instincts as they use new technology to help patients. Report